News
Shortcuts from other journals
Meta-analysis confirms rosiglitazone's poor safety record
BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7620.586-b (Published 20 September 2007) Cite this as: BMJ 2007;335:586
Rosiglitazone is still approved by the US Food and Drugs Administration (FDA) for the treatment of type 2 diabetes, despite evidence from meta-analyses that it is associated with an increased risk of heart attack and heart failure⇑.
A third meta-analysis, this time …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.